Tranexamic Acid Prophylaxis for Heterotopic Ossification in Elbow Fracture-Dislocation Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-21

Study Completion Date

2023-09-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Heterotopic ossification (HO) following elbow fracture-dislocation is a well-recognized condition that can lead to reduced range of motion, increased pain, and the necessity for repeat surgeries.

Inflammation serves as a pivotal initiating factor in the formation of (HO) following a traumatic event. The inflammatory cascade triggered can lead to the dysregulation of tissue homeostasis, thereby promoting the aberrant formation of ectopic bone. Tranexamic acid (TXA), a Food and Drug Administration (FDA) approved synthetic antifibrinolytic agent, has garnered significant attention for its potential to mitigate the inflammatory response in the context of orthopaedic surgical procedures.

This study aims to investigate the hypothesis that reducing soft tissue hematoma during elbow fracture-dislocation surgery through the intraoperative administration of TXA, can alleviate the occurrence or severity of ectopic bone formation.

Methods: A prospective randomized study was conducted on patients with elbow fracture-dislocation who underwent surgery between 2016 and 2022. A total of 50 patients were enrolled and randomly assigned to two groups. The first group received 1 gram of intravenous tranexamic acid before the operation, followed by an additional 1 gram intravenously during wound closure. The second group did not receive any anti-bleeding medication. Patients were followed up at intervals of 2 weeks, 6 weeks, 3 months, and as needed after the surgery. At the end of the follow-up period, there were 23 patients in the first group and 24 in the second group, with a median follow-up duration of 12.7 months. All patients did not receive any other form of HO prophylaxis. Postoperative radiographs and clinical outcomes were assessed and recorded.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Naproxen for the Prevention of HO After Complex Elbow Trauma

NCT00586365

Heterotopic Ossification

WITHDRAWN PHASE4

Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma

NCT00991887

Elbow Fracture

TERMINATED NA

Plating of Humeral Shaft Fractures in Multiple Trauma Patients.

NCT00720681

Humeral Fractures Multiple Trauma

COMPLETED

Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture

NCT02223572

Hip Fractures Osteoporotic Fractures Osteoporosis

UNKNOWN NA

HO Prophylaxis Therapy for Distal Humerus Fractures

NCT03724422

Heterotopic Ossification Humeral Fractures Radiation Therapy

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Elbow Dislocation Heterotopic Ossification

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

With tranexamic acid

Patient undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intraoperatively.

The patients received intravenous 1 gram tranexamic acid in 100ml normal saline 30 minutes before skin incision and a second dose of intravenous 1 gram tranexamic acid in 100 ml of normal saline during wound closure.

Group Type EXPERIMENTAL

with Tranexamic acid

Intervention Type DRUG

Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively

Without tranexamic acid

Patient undergoing surgery for elbow fracture-dislocation randomized to be treated without tranexamic acid intraoperatively

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

with Tranexamic acid

Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. traumatic non-pathological elbow fracture-dislocation.
2. age 18 years or older.
3. presentation within 2 weeks of injury.
4. Willingness to participate in the study

Exclusion Criteria

1. Inability to provide consent for research participation.
2. Active infection in the operated limb.
3. Previous hip fracture.
4. Head injury.
5. History of deep vein thrombosis (DVT).
6. History of venous thromboembolism (VTE).
7. Ischemic heart event within the last six months.
8. Stroke (CVA) within the last six months.
9. Coagulopathies.
10. Pregnancy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No